ClinicalTrials.gg
RecruitingNCT07579936Updated May 12, 2026

A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

A Phase 2 interventional study of SAL056 56.5μg and Intervention Group 1 in Postmenopausal Women With Osteoporosis, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
19th of 57
200 · median 120
Started
2026
with 5 others
Phase 2
3 of 87
1 open now
Primary completion
2026-07
later than 15 of 32 live
Registered
83rd of 87
by date
Lead sponsor
3 of 87
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 87 studies in Osteoporosis with a site in China, this one is the 19th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 15 of the 32 other live ones, and was the 83rd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.

Read the detailed description

This study will randomly assign 200 eligible trial participants to either the intervention group or the control group, with each treatment group receiving an 8-week course of the investigational drug. By comparing the incidence of safety events between the groups at the end of the treatment period, the safety differences among the four different medication regimens will be evaluated.

The study is primarily divided into a screening period (up to 4 weeks before administration), a treatment period (8 weeks), and a safety follow-up period of 1 week, requiring a total of 7 visits.

03

Conditions studied

  • Postmenopausal Women With Osteoporosis

Browse trials for

Keywords

  • Postmenopausal Women With Osteoporosis
  • high risk of fracture
  • Teriparatide
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Female, with independent mobility, 45 years ≤ age ≤ 80 years; 2.Natural menopause for ≥3 years, or surgical menopause for ≥3 years (surgery must be performed after age 40); for women with surgical menopause, follicle-stimulating hormone >40 mIU/mL is required; 3.18 ≤ ≤ 30 kg/m²; 4.Previous definitive diagnosis of osteoporosis; 5.Patients who are able to independently go to the hospital to receive injections of the drug; 6. Voluntarily participate in this trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Received teriparatide treatment within 1 month prior to screening;
  2. Patients with secondary osteoporosis, such as Cushing's syndrome, hyperprolactinemia, malabsorption syndrome or various gastrointestinal diseases related to malabsorption (such as Crohn's disease, chronic pancreatitis, etc.), rheumatoid arthritis, gout, multiple myeloma, etc.;
  3. Patients with other diseases affecting calcium or bone metabolism, including hyperparathyroidism or hypoparathyroidism, hyperthyroidism or hypothyroidism (patients with hyperthyroidism or hypothyroidism receiving stable treatment with normal hormone levels are eligible; or patients with hypothyroidism where 5.5 mIU/L \< thyroid-stimulating hormone ≤ 10.0 mIU/L but free thyroxine is within normal range are eligible), osteogenesis imperfecta, osteomalacia, Paget's disease of bone, hypercalcemia, hypocalcemia, active urolithiasis, etc.;
  4. Patients who require treatment with other anti-osteoporosis drugs during the trial or long-term/continuous use of digitalis glycosides such as digoxin;
  5. Patients with severe renal disease (serum creatinine >1.5 times the ), uncontrolled hypertension [systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg], severe heart disease (such as myocardial infarction, unstable angina pectoris, heart failure with functional class III-IV, severe arrhythmias, etc.), cerebral infarction (excluding lacunar cerebral infarction) or occlusive arteriosclerosis, malignant tumors, and those with other serious underlying diseases;
  6. Patients with esophageal abnormalities that cause delayed esophageal emptying (such as reflux esophagitis, esophageal stricture or achalasia) or those with difficulty swallowing;
  7. Abnormal laboratory findings detected during the screening period, including any of the following abnormal indicators:

1) Alkaline phosphatase >1.3 times the upper limit of normal; 2) or aspartate aminotransferase >3.0 times the upper limit of normal; 3)Total >1.5 times the upper limit of normal; 4) ≥8.5%; 5)White blood cell count \<3.0×10⁹/L, or \<100g/L, or count \<90×10⁹/L; 6)Parathyroid hormone >1.5 times the upper limit of normal; 8. Positive for virus antibody, or Treponema pallidum antibody, or antibody; or positive for surface antigen (HBsAg) with peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) titer ≥1×103 copies/mL (if HBsAg is positive and peripheral blood HBV DNA titer \<1×103 copies/mL, the trial participant is eligible if the investigator considers the participant's chronic hepatitis B to be in a stable phase and will not increase the risk to the trial participant); 9. History of major surgery (excluding fracture surgery) within 6 months prior to signing the form, or planned major surgery during the study period; 10. Known history of organ transplantation; 11. History of drug abuse within 6 months prior to informed consent; 12. Individuals with known allergy to the drug; 13. Patients who have previously received radiation therapy to the skeletal system; 14. Individuals with mental illness or cognitive impairment due to any cause; 15. Patients deemed unsuitable to participate in this study by researchers based on risk-benefit considerations.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Control group

    SAL056 56.5μg administered once weekly for 8 weeks

    Drug: SAL056 56.5μg

  • Other
    Intervention Group 1

    Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks;

    Drug: Intervention Group 1

  • Other
    Intervention Group 2

    Teriparatide Injection daily formulation administered for 4 weeks, followed by SAL056 for 4 weeks;

    Drug: Intervention Group 2

  • Other
    Intervention Group 3

    SAL056 28.2μg administered twice weekly for 8 weeks.

    Drug: Intervention Group 3

Interventions

  • DrugSAL056 56.5μg

    SAL056 56.5μg administered once weekly for 8 weeks

  • DrugIntervention Group 1

    Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks.

  • DrugIntervention Group 2

    Teriparatide Injection daily formulation administered for 4 weeks, followed by SAL056 for 4 weeks.

  • DrugIntervention Group 3

    SAL056 28.2μg administered twice weekly for 8 weeks.

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) between each intervention group and the control group during the treatment period,about 10weeks

    Time frame: during the treatment period,about 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

Of 42 phase 2 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 12, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Nov 30, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07579936
Collaborators
Salubris (Suzhou) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Apr 30, 2026
Primary completion
Jul 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Weishi Li, Professor
Contact
weishi_li@aliyun.com
13501358705

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion